Trial abstract · §3
SURVO-PH2-MASH — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Histological improvement in metabolic dysfunction-associated steatohepatitis without worsening of fibrosis | Improvement in 62 % to 83 % across doses versus 18 % with placebo | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Survodutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 52.0 | 18.0 | Phase 2 obesity, highest dose |
| Vomiting | 37.0 | 4.0 | Phase 2 obesity |
| Constipation | 29.0 | 10.0 | Phase 2 obesity |
| Increased heart rate | — | — | Dose-dependent, attributed to the glucagon arm |
| Discontinuation for adverse events | 25.0 | 5.0 | Phase 2 obesity, highest dose |
Compound Evidence Institute · CEI-TR-0057/3 · https://compoundevidence.com/trials/survo-ph2-mash/results/ · retrieved 30 July 2026